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Background
The management of patients with severe refractory
asthma (SRA) is a difficult task that may benefit from
the use of non-invasive assessment by biomarkers. Inter-
leukin (IL)-13 is a cytokine with a central role in the
TH2 response. The object of this study was the assess-
ment of IL-13 as a biomarker of asthma control in
patients with SRA.
Method
We recruited 170 patients (47 with SRA) from two Uni-
versity asthma clinics. Patients were submitted to pulmon-
ary function testing, measurement of fractional exhaled
nitric oxide (FeNO), and sputum induction with calcula-
tion of inflammatory cells and measurement of IL-13 in
the supernatant. Asthma control test (ACT) was used for
evaluation of asthma control (ACT values >19 identified
well-controlled asthma). Severe refractory asthma was
defined by the ATS criteria.
Results
IL-13 in sputum supernatant was increased in patients
with SRA compared to patients with mild-to-moderate
asthma [median (IQR): 156 (80-245) pg/mL vs. 78 (66-
103) pg/mL, p<0.001], as well as in patients with persis-
tent airflow obstruction [99 (71-199) pg/mL vs. 80 (66-
105) pg/mL, p=0.0081]. IL-13 presented good diagnostic
accuracy for the detection of not-well-controlled asthma
in the whole group [specificity 94.2%, sensitivity 80.6%
for a cut-off point of ≤ 156 pg/mL; area under the curve
(AUC) 0.920]. The diagnostic accuracy of IL-13 was
superior to FeNO or sputum eosinophils in patients
with SRA (AUC 0.981 vs. 0.688 vs. 0.645 respectively;
p<0.001).
Conclusion
IL-13 in induced sputum may represent a useful index
of disease control in patients with SRA. The better diag-
nostic accuracy of IL-13, compared to FeNO and spu-
tum eosinophils, indicates a central role of this mediator
in SRA.
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